Welcome to our dedicated page for Emergent Biosolutions news (Ticker: EBS), a resource for investors and traders seeking the latest updates and insights on Emergent Biosolutions stock.
Emergent BioSolutions Inc. (NYSE: EBS) regularly issues news and updates that reflect its focus on public health threats and pharmaceutical preparation manufacturing. Company announcements highlight developments across its commercial naloxone franchise, medical countermeasures portfolio, manufacturing network and financial performance, providing context for how Emergent pursues its stated mission to protect and save lives.
News items frequently cover product and regulatory milestones, such as U.S. Food and Drug Administration approvals and supplemental applications. Examples include FDA approval of over‑the‑counter NARCAN® Naloxone HCl Nasal Spray 4 mg and approval of a supplemental Biologics License Application for raxibacumab manufacturing at Emergent’s Winnipeg, Canada facility. Releases also describe new packaging options, such as the NARCAN® Nasal Spray carrying case designed to make naloxone easier to carry and more discreet.
Emergent’s news flow also features government contracts and contract modifications for medical countermeasures. Recent announcements describe delivery orders and options to supply BioThrax® (Anthrax Vaccine Adsorbed), ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), TEMBEXA® and BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] to U.S. government agencies responsible for preparedness and response.
Investors and observers can also find financial and corporate updates, including quarterly earnings releases, segment performance commentary, debt prepayments under term loan facilities, and notices of presentations at healthcare conferences. Additional news addresses board‑level changes and corporate governance matters.
Other communications focus on public health initiatives and collaborations, such as support for opioid poisoning awareness observances, partnerships aimed at increasing workplace access to naloxone, and collaboration with PANTHER and Africa CDC on the MpOx Study in Africa. Together, these updates offer insight into how Emergent’s products, contracts, research collaborations and financial decisions relate to its role in addressing health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies.
Emergent BioSolutions (NYSE: EBS) commends the U.S. House of Representatives for implementing over-the-counter (OTC) naloxone availability at all AED locations in its buildings. The initiative, led by Representative Buddy Carter (R-GA), aims to provide immediate access to life-saving treatment for potential opioid overdoses.
The company highlights that its NARCAN® Nasal Spray, the first OTC opioid overdose reversal treatment, has contributed to reducing overdose deaths according to CDC data. Since 2016, over 85 million doses have been distributed across the U.S. and Canada. As the leading U.S. supplier of nasal naloxone, Emergent offers multiple products including NARCAN® 4mg, KLOXXADO® 8mg, and various convenience kits.
Emergent BioSolutions (NYSE:EBS) announced the publication of a review article in Expert Review of Anti-infective Therapy evaluating brincidofovir as a potential treatment for mpox. The article examines brincidofovir's in vitro and in vivo data, human case studies, and its current evaluation in the Democratic Republic of Congo.
The publication comes amid ongoing global mpox outbreaks, with the WHO declaring a Public Health Emergency of International Concern (PHEIC) on August 14, 2024. Brincidofovir is being evaluated in the MpOx Study in Africa (MOSA), a double-blind, placebo-controlled clinical trial that began in January 2025, conducted in partnership with PANTHER and funded by Horizon Europe and Africa CDC.
Emergent BioSolutions (NYSE:EBS) has scheduled its second quarter 2025 financial results conference call for August 6, 2025, at 5:00 PM ET. The company will provide access to the call through multiple channels, including a live webcast available on their Investors webpage.
Telephone participants must pre-register through a provided link to receive dial-in information and unique access credentials. A replay of the conference call will be made available on the company's Investors page after the event.
Emergent BioSolutions (NYSE:EBS) has secured a significant $51.9 million contract modification from the Administration for Strategic Preparedness and Response (ASPR) for its CNJ-016® (VIGIV) treatment. The contract is part of the U.S. government's smallpox preparedness strategy, extending an existing 10-year agreement for additional doses of VIGIV, which treats complications from smallpox vaccination.
The announcement follows Emergent's recent BAT® (Botulism Antitoxin Heptavalent) contract amendment with ASPR. VIGIV is a 5% Liquid Immune Globulin treatment indicated for various vaccinia vaccination complications, including eczema vaccinatum and progressive vaccinia, though not for postvaccinial encephalitis.
Emergent BioSolutions (NYSE:EBS) has expanded its NARCANDirect® online distribution network to include KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, complementing its existing NARCAN® 4 mg nasal spray offering. The expansion, effective July 1, 2025, follows Emergent's acquisition of KLOXXADO's exclusive commercial rights in the U.S. and Canada in January 2025.
The platform serves qualified direct purchasers including emergency services, law enforcement, schools, and community-based programs. The company is also introducing Convenience Kits featuring CPR masks and nitrile gloves. This expansion comes as CDC data shows a 27% decrease in drug overdose deaths in 2024, though recent data indicates a slight uptick of 1,400 deaths between January 2024 and January 2025.
Emergent BioSolutions (NYSE: EBS) has announced its participation in multiple upcoming investor conferences in May and June 2025. The company's executive management team will attend:
- RBC Global Healthcare Conference in New York (May 20) featuring a fireside chat at 3:35 pm ET
- Goldman Sachs Leveraged Finance Conference in Dana Point, California (May 29)
- Benchmark's 5th Annual Healthcare House Call Virtual Investor Conference (May 29)
- Jefferies Global Healthcare Conference in New York (June 5) with a presentation at 1:25 pm ET
Virtual attendance options are available for select events, and presentation replays will be accessible through Emergent's website investor page.
FAQ
What is the current stock price of Emergent Biosolutions (EBS)?
What is the market cap of Emergent Biosolutions (EBS)?
